Literature DB >> 1713358

FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats.

P M Markus1, X Cai, W Ming, A J Demetris, J J Fung, T E Starzl.   

Abstract

Severe graft-versus-host disease was induced by transplantation of ACI rat bone marrow and spleen cells into irradiated Lewis rat recipients. Treatment with FK 506 or cyclosporine A (CsA) was started after clinical and histologic evidence of acute GVHD was present. A 14-day course of FK 506 at 1.0 mg/kg/day could rescue 100% of the animals suffering from GVHD. In contrast only one half of the animals treated with CsA at a high dose of 25 mg/kg/day recovered. After cessation of immunosuppressive therapy, FK 506-treated animals displayed a marked prolonged disease-free interval as compared to CsA-treated bone marrow recipients. Recurrence of the disease in these animals could be prevented when FK 506 treatment was continued after the induction period with a low maintenance dose of 0.1 mg/kg/day every other day.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1713358      PMCID： PMC2956606     

Source DB:  PubMed          Journal:  Surgery        ISSN： 0039-6060            Impact factor:   3.982


  25 in total

Review 1.  Bone-marrow transplantation (second of two parts).

Authors:  E D Thomas; R Storb; R A Clift; A Fefer; L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-24       Impact factor: 91.245

2.  Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats.

Authors:  T Ochiai; K Nakajima; M Nagata; S Hori; T Asano; K Isono
Journal:  Transplantation       Date:  1987-12       Impact factor: 4.939

3.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

Review 4.  Allogeneic bone-marrow transplantation.

Authors:  R Storb; E D Thomas
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

5.  Use of cyclosporin A in allogeneic bone marrow transplantation in the rat.

Authors:  P J Tutschka; W E Beschorner; A C Allison; W H Burns; G W Santos
Journal:  Nature       Date:  1979-07-12       Impact factor: 49.962

6.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

7.  Pathological changes developing in the rat during a 3-week course of high dosage cyclosporin A and their reversal following drug withdrawal.

Authors:  A W Thomson; P H Whiting; J T Blair; R J Davidson; J G Simpson
Journal:  Transplantation       Date:  1981-10       Impact factor: 4.939

Review 8.  The major histocompatibility complex of the rat.

Authors:  T J Gill; H W Kunz; D N Misra; A L Hassett
Journal:  Transplantation       Date:  1987-06       Impact factor: 4.939

9.  Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.

Authors:  S Todo; Y Ueda; J A Demetris; O Imventarza; M Nalesnik; R Venkataramanan; L Makowka; T E Starzl
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982

10.  Effect of cyclosporin A on the anti-leukaemia action associated with graft-versus-host disease.

Authors:  S Denham; S Attridge; R K Barfoot; P Alexander
Journal:  Br J Cancer       Date:  1983-06       Impact factor: 7.640
View more
  8 in total

1.  Management of intestinal transplantation in humans.

Authors:  K Abu-Elmagd; J J Fung; J Reyes; A Casavilla; D H Van Thiel; Y Iwaki; V Warty; N Nikolaidis; J Block; K Nakamura
Journal:  Transplant Proc       Date:  1992-06       Impact factor: 1.066

2.  Graft-versus-host disease following liver transplantation.

Authors:  N D Heaton; A S Reece; K C Tan
Journal:  J R Soc Med       Date:  1992-06       Impact factor: 5.344

3.  Overview of FK506 in transplantation.

Authors:  J J Fung; K Abu-Elmagd; S Todo; R Shapiro; A Tzakis; M Jordan; J Armitage; A Jain; M Alessiani; M Martin
Journal:  Clin Transpl       Date:  1990

4.  Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506.

Authors:  P M Markus; X Cai; W Ming; A J Demetris; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1991-10       Impact factor: 4.939

Review 5.  The many faces of multivisceral transplantation.

Authors:  T E Starzl; S Todo; A Tzakis; M Alessiani; A Casavilla; K Abu-Elmagd; J J Fung
Journal:  Surg Gynecol Obstet       Date:  1991-05

Review 6.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

7.  Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat.

Authors:  J M Langrehr; N Murase; P M Markus; X Cai; P Neuhaus; W Schraut; R L Simmons; R A Hoffman
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

8.  Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506.

Authors:  N Murase; A J Demetris; J Woo; M Tanabe; T Furuya; S Todo; T E Starzl
Journal:  Transplantation       Date:  1993-01       Impact factor: 4.939
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.